Pharmaceutical composition
US5955427A · kind A · utility
4Cited by
28References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 8, 1997 |
| Grant date | Sep 21, 1999 |
| Priority date | — |
| Expiry date | Dec 8, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising a polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate surfactants. Preferred polypeptides stabilized are bactericidal/permeability increasing (BPI) protein, biologically active fragments of BPI, biologically active analogs of BPI, and biologically active variants of BPI.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.